Table 1.

Dose and day-dependent healing capacities of BT and TF against indomethacin-induced stomach ulceration in mice^a.

Group	Drug dose (mg/kg)	Period of treatment (days)	Macroscopic damage scores (MDS)b	MDS reduction (%)c
3rd day-ulcerated untreated	—		3.39 ± 0.24	0
5th day-ulcerated untreated			1.21 ± 0.15
7th day-ulcerated untreated			0.68 ± 0.07
BT-treated	10	3	2.64 ± 0.22*	22.13
BT-treated	20	3	1.89 ± 0.17**	44.25
BT-treated	30	3	1.47 ± 0.15†	56.64
BT-treated	40	3	0.88 ± 0.06†,#	74.05
BT-treated	50	3	0.83 ± 0.07†,#	75.52
BT-treated	40	7	0.55 ± 0.12	83.78
TF-treated	0.5	3	1.12 ± 0.13†	66.96
TF-treated	1	3	0.81 ± 0.07†,Ψ	76.4
TF-treated	2.5	3	0.74 ± 0.06†,Ψ	78.17
TF-treated	4	3	0.62 ± 0.07†,Ψ	82.3
TF-treated	5	3	0.53 ± 0.06†,Ψ	84.36
TF-treated	1	7	0.46 ± 0.08	86.44

^aStomach ulceration in mice was induced by oral administration of indomethacin (18 mg/kg). Different doses of BT and TF were used for these experiments. ^bThe MDS were measured on the 3rd, 5th, and 7th day after indomethacin administration and the values are mean ± S.E.M of three independent experiments, each with 5 mice/group. ^cConsidering a MDS value of 100 for the 3rd day untreated mice. *P < 0.05, **P < 0.01, ^† P < 0.001 compared to ulcerated mice; ^# P < 0.05 compared to BT (30 mg/kg) treatment; ^Ψ P < 0.05 compared to TF (0.5 mg/kg) treatment.